|Exchange:||NASDAQ national market|
|Stock:||OraSure Technologies, Inc.|
|Industry:||Medical Instruments & Supplies|
|OraSure Technologies, Inc., was formed in May 2000 under Delaware law solely for the purposes of combining two companies, STC Technologies, Inc. and Epitope, Inc. and changing the state of incorporation of Epitope from Oregon to Delaware. The Company is involved in development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its proprietary oral fluid technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. It also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. Its diagnostic products include tests that are performed at the point of care and tests that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. One of its products has been sold in the over-the-counter (‘OTC’) or consumer retail markets in North America, Europe, Central and South America, and Australia. In vitro diagnostic testing is the process of analyzing oral fluid, blood, urine and other bodily fluids or tissue for the presence of specific substances or markers. In August 2011, it has completed the acquisition of DNA Genotek Inc. (‘DNAG’), a Company based in Ottawa, Canada. DNAG manufactures and sells oral fluid collection kits that are used to collect samples of genetic material (DNA and RNA) for molecular testing in the academic research, clinical, pharmacogenomics, and personalized medicine, animal and livestock genetics markets. DNAG’s main product, the Oragene® sample collection kit, provides an all-in-one system for the collection, stabilization, transportation and storage of DNA from saliva. DNAG serves customers in many countries worldwide, including many research universities and hospitals in the world. The Company owns rights to trademarks and service marks that are necessary to conduct its business as currently operated. In the United States, it owns the OraSure®, Intercept®, OraQuick®, OraQuick ADVANCE®, and Q.E.D®. The competitors include specialized biotechnology firms, pharmaceutical companies with biotechnology divisions and medical diagnostic companies like Johnson & Johnson, Bio-Rad Laboratories and Abbott. The Company subject to other federal and state laws targeting fraud and abuse in the healthcare industry, including false claims laws and marketing conduct laws and laws constraining the sales, marketing and other promotional activities of manufacturers of medical devices by limiting the kinds of financial arrangements, including sales programs, with physicians, hospitals, laboratories and other potential purchasers of medical devices.|
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.